Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects

Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccinat...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 63; no. 4; pp. 293 - 298
Main Authors Roos-van Eijndhoven, D.G., Cools, H.J.M., Westendorp, R.G.J., Ten Cate-Hoek, A.J., Knook, D.L., Remarque, E.J.
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.04.2001
Wiley-Liss
Subjects
Online AccessGet full text
ISSN0146-6615
1096-9071
DOI10.1002/1096-9071(200104)63:4<293::AID-JMV1004>3.0.CO;2-C

Cover

Loading…
Abstract Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997–98. The first vaccine dose (15 or 30 μg) was given on Day 0 followed by a booster dose (placebo or 15 μg) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 μg and placebo, (ii) 15 μg and 15 μg booster, (iii) 30 μg and placebo and (iv) 30 μg and 15 μg booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% CI, 6% to 24%, P = 0.001) higher as compared to the standard 15 μg dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% CI, 9% to 19%, P = 0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination. J. Med. Virol. 63:293–298, 2001. © 2001 Wiley‐Liss, Inc.
AbstractList Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997-98. The first vaccine dose (15 or 30 microg) was given on Day 0 followed by a booster dose (placebo or 15 microg) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 microg and placebo, (ii) 15 microg and 15 microg booster, (iii) 30 microg and placebo and (iv) 30 microg and 15 microg booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% CI, 6% to 24%, P = 0.001) higher as compared to the standard 15 microg dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% CI, 9% to 19%, P = 0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination.
Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997–98. The first vaccine dose (15 or 30 μg) was given on Day 0 followed by a booster dose (placebo or 15 μg) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 μg and placebo, (ii) 15 μg and 15 μg booster, (iii) 30 μg and placebo and (iv) 30 μg and 15 μg booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% CI, 6% to 24%, P = 0.001) higher as compared to the standard 15 μg dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% CI, 9% to 19%, P = 0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination. J. Med. Virol. 63:293–298, 2001. © 2001 Wiley‐Liss, Inc.
Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997-98. The first vaccine dose (15 or 30 mu g) was given on Day 0 followed by a booster dose (placebo or 15 mu g) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 mu g and placebo, (ii) 15 mu g and 15 mu g booster, (iii) 30 mu g and placebo and (iv) 30 mu g and 15 mu g booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% Cl, 6% to 24%, P=0.001) higher as compared to the standard 15 mu g dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% Cl, 9% to 19%, P=0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination.
Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997-98. The first vaccine dose (15 or 30 microg) was given on Day 0 followed by a booster dose (placebo or 15 microg) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 microg and placebo, (ii) 15 microg and 15 microg booster, (iii) 30 microg and placebo and (iv) 30 microg and 15 microg booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% CI, 6% to 24%, P = 0.001) higher as compared to the standard 15 microg dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% CI, 9% to 19%, P = 0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination.Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized clinical trial was performed to determine the effect of a double dose and booster vaccination on antibody responses after influenza vaccination. A total of 815 patients (median age 83 years, median disability score 8, median disease categories 2 and median number of medications 4) residing in 14 nursing homes in the Netherlands were vaccinated during the influenza season 1997-98. The first vaccine dose (15 or 30 microg) was given on Day 0 followed by a booster dose (placebo or 15 microg) on Day 84. Blood samples were taken before and 25 days after vaccination. There were four treatment groups: (i) 15 microg and placebo, (ii) 15 microg and 15 microg booster, (iii) 30 microg and placebo and (iv) 30 microg and 15 microg booster. Geometric mean antibody titers of those receiving the double vaccine dose was 15% (95% CI, 6% to 24%, P = 0.001) higher as compared to the standard 15 microg dose. A booster dose, given 84 days after the first vaccination, yielded postvaccination titters that were 14% (95% CI, 9% to 19%, P = 0.001) higher as compared to placebo. Subgroup analysis did not reveal patient groups that had a proportionally greater benefit from adapted vaccination strategies. It is concluded that higher antibody responses can be achieved in frail elderly people by a double vaccine dose or a booster vaccination.
Author Remarque, E.J.
Knook, D.L.
Westendorp, R.G.J.
Cools, H.J.M.
Roos-van Eijndhoven, D.G.
Ten Cate-Hoek, A.J.
Author_xml – sequence: 1
  givenname: D.G.
  surname: Roos-van Eijndhoven
  fullname: Roos-van Eijndhoven, D.G.
  organization: Department of General Practice and Nursing Home Medicine, Leiden University Medical Center, The Netherlands
– sequence: 2
  givenname: H.J.M.
  surname: Cools
  fullname: Cools, H.J.M.
  organization: Department of General Practice and Nursing Home Medicine, Leiden University Medical Center, The Netherlands
– sequence: 3
  givenname: R.G.J.
  surname: Westendorp
  fullname: Westendorp, R.G.J.
  organization: Section of Gerontology, Dept. of Internal Medicine, Leiden University Medical Center, The Netherlands
– sequence: 4
  givenname: A.J.
  surname: Ten Cate-Hoek
  fullname: Ten Cate-Hoek, A.J.
  organization: Psychogeriatric Nursing Home Mariahoeve, The Hague, The Netherlands
– sequence: 5
  givenname: D.L.
  surname: Knook
  fullname: Knook, D.L.
  organization: Section of Gerontology, Dept. of Internal Medicine, Leiden University Medical Center, The Netherlands
– sequence: 6
  givenname: E.J.
  surname: Remarque
  fullname: Remarque, E.J.
  email: E.J.Remarque@LUMC.NL
  organization: Section of Gerontology, Dept. of Internal Medicine, Leiden University Medical Center, The Netherlands
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=920196$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11241460$$D View this record in MEDLINE/PubMed
BookMark eNqVkVuL1DAYQIusuBf9CxIQRB86frk0mYwiLFXXlVmHlfXyFtL2K3TNNGPSus7-ejPM7PgiiE8J6fkOac5xdtD7HrNMU5hQAPaCgpa5BkWfMQAK4rnkM_GKaT6bnZ6_yT9cfEmYeM0nMCkXL1le3suO9jMH2RFQIXMpaXGYHcd4DQBTzdiD7JBSJtI3OMpuPtm-8cvuFhtS-34I3rm0HUJnHfEtiRh8wLjyfcRIBk8aP1YO0xKRpFFSeR8HDKTrWzdif2vJT1vXXW-HzvfplLTBdo6gazC4NYljdY31EB9m91vrIj7arSfZ1bu3V-X7fL44Oy9P53nNFRV5JZlWUCvFOG8EFJguLqa01bRuARXFylKU0wI4QMNpK0TBJBWqwMbSRvGT7OlWuwr-x4hxMMsu1uic7dGP0Sip0wCj_wSpmgopimkCH-_AsVpiY1ahW9qwNndPmoAnO8DG2rr0-33dxT2nGVAtE3W5pergYwzY_hGB2cQ3m5BmE9Js4xvJjTApvjEpvtnFN9yAKReGmTI5P2-dN53D9X8I_-67O0refOvtUulfe68N341UXBXm68czw-Z6zi4vviXrbzQ3zj0
CODEN JMVIDB
Cites_doi 10.1093/geront/10.1_Part_1.20
10.1016/0264-410X(89)90150-3
10.1001/jama.1994.03520210045030
10.1016/0166-3542(90)90026-4
10.1017/S0022172400022610
10.1093/ageing/21.3.182
10.1001/jama.1985.03350320060017
10.1128/JCM.25.9.1763-1765.1987
10.1093/oxfordjournals.aje.a115038
10.1111/j.1532-5415.1992.tb01938.x
10.1093/oxfordjournals.aje.a115874
10.1016/0264-410X(93)90311-K
10.1093/infdis/161.2.333
10.1136/bmj.312.7037.1015
10.1016/0264-410X(93)90333-S
10.1111/j.1532-5415.1988.tb06152.x
10.1111/j.1532-5415.1988.tb01802.x
10.1093/infdis/153.4.805
10.1001/jama.1980.03310220045026
10.1093/infdis/167.3.584
10.1017/S0950268800031034
10.1056/NEJM199409223311206
10.1016/S0531-5565(98)00060-6
10.1086/314540
10.1001/archinte.158.16.1769
10.1111/j.1532-5415.1992.tb02108.x
10.1002/(SICI)1096-9071(199805)55:1<82::AID-JMV13>3.0.CO;2-1
ContentType Journal Article
Copyright Copyright © 2001 Wiley‐Liss, Inc.
2001 INIST-CNRS
Copyright_xml – notice: Copyright © 2001 Wiley‐Liss, Inc.
– notice: 2001 INIST-CNRS
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
DOI 10.1002/1096-9071(200104)63:4<293::AID-JMV1004>3.0.CO;2-C
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

AIDS and Cancer Research Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1096-9071
EndPage 298
ExternalDocumentID 11241460
920196
10_1002_1096_9071_200104_63_4_293__AID_JMV1004_3_0_CO_2_C
JMV1004
ark_67375_WNG_2L9L2QMX_6
Genre article
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Netherlands
GeographicLocations_xml – name: Netherlands
GrantInformation_xml – fundername: Praeventiefonds
  funderid: 28‐2732
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
ID FETCH-LOGICAL-c3714-b62970c77233d405e124481f91cf0e71eba1e6850300d31f445261475eda1d73
IEDL.DBID DR2
ISSN 0146-6615
IngestDate Thu Jul 10 19:20:29 EDT 2025
Fri Jul 11 03:09:24 EDT 2025
Wed Feb 19 02:33:35 EST 2025
Mon Jul 21 09:15:48 EDT 2025
Tue Jul 01 01:33:05 EDT 2025
Wed Jan 22 16:24:23 EST 2025
Wed Oct 30 09:52:53 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Human
Immunoprotection
Booster vaccination
Vaccination
Orthomyxoviridae
Vaccine
Influenzavirus
Dose activity relation
Virus
Immunogenicity
Clinical trial
Elderly
Humoral immunity
Language English
License http://doi.wiley.com/10.1002/tdm_license_1.1
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3714-b62970c77233d405e124481f91cf0e71eba1e6850300d31f445261475eda1d73
Notes Informed consent was obtained from all participants of the current study. Guidelines for human experimentation of the Leiden University were followed in the conduct of the research. The study was approved by the Leiden University Medical Ethics Committee.
ark:/67375/WNG-2L9L2QMX-6
ArticleID:JMV1004
istex:7F821C57D29E6D321A4C02626E1EB70C024E0C6A
Praeventiefonds - No. 28-2732
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
PMID 11241460
PQID 17846458
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_76952621
proquest_miscellaneous_17846458
pubmed_primary_11241460
pascalfrancis_primary_920196
crossref_primary_10_1002_1096_9071_200104_63_4_293__AID_JMV1004_3_0_CO_2_C
wiley_primary_10_1002_1096_9071_200104_63_4_293_AID_JMV1004_3_0_CO_2_C_JMV1004
istex_primary_ark_67375_WNG_2L9L2QMX_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2001
PublicationDateYYYYMMDD 2001-04-01
PublicationDate_xml – month: 04
  year: 2001
  text: April 2001
PublicationDecade 2000
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: New York, NY
– name: United States
PublicationTitle Journal of medical virology
PublicationTitleAlternate J. Med. Virol
PublicationYear 2001
Publisher John Wiley & Sons, Inc
Wiley-Liss
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley-Liss
References Arden NH, Patriarca PA, Lui K-J, Harmon MW, Brandon FB, Kendal AP. 1986. Safety and immunogenicity of a 45 μg supplemental dose of inactivated split-virus Influenza B vaccine in the elderly. J Infect Dis 153:805-806.
de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJD, Westendorp RGJ, Knook DL. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 179:31-36.
Nichol KL, Wuorenma J, von Sternberg T. 1998. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158:1769-1776.
Powers DC, Murphy BR, Fries LF, Adler WH, Clements ML. 1992. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 40:163-167.
Govaert ThME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. 1994. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 272:1661-1665.
Sullivan KM, Monto AS, Foster DA. 1990. Antibody response to inactivated influenza vaccines of various antigenic concentrations. J Infect Dis 161:333-335.
Beyer WEPh, Palache AM, Baljet M, Masurel N. 1989. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7:385-394.
Sprenger MJW, van Naelten MAMG, Mulder PGH, Masurel N. 1989. Influenza mortality and excess deaths in the elderly, 1967-82. Epidemiol Infect 103:633-641.
Nichol KL, Margolis KL, Wuorenma J, von Sternberg TL. 1994. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331:778-784.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene Cambridge 70:767-777.
Katz S, Downs TD, Cash HR, Grotz RC. 1970. Progress in the development of the index of ADL. Gerontologist 10:20-30.
Remarque EJ, de Bruijn IA, Boersma WJA, Masurel N, Ligthart GJ. 1998. Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 55:82-87.
Peters NL, Meiklejohn G, Jahnigen DW. 1988. Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J Am Geriatr Soc 36:593-599.
Remarque EJ, Cools HJM, Boere TJ, van der Klis RJ, Masurel N, Ligthart GJ. 1996. Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home. Br Med J 312:1015-1015.
Levine M, Beattie BL, McLean DM. 1987. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ 137:722-726.
Reuman PD, Bernstein DI, Keely SP, Sherwood JR, Young EC, Schiff GM. 1990. Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition. Antiviral Res 13:103-110.
Coles FB, Balzano GJ, Morse DL. 1992. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc 40:589-592.
Barker WH, Mullooly JP. 1980. Influenza vaccination of elderly persons: reduction in pneumonia an influenza hospitalizations and deaths. JAMA 244:2547-2549.
Longini IM, Koopman JS, Haber M, Cotsonis GA. 1988. Statistical interference for infectious diseases. Risk-specific household and community transmission parameters. Am J Epidemiol 128:845-859.
Gross PA, Weksler ME, Quinnan GV, Douglas RG, Gaerlan PF, Denning CR. 1987. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 25:1763-1765.
Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. 1991. Age distribution of patients with medically-attended illness caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 133:296-304.
Powers DC, Belshe RB. 1993. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 167:584-592.
Remarque EJ, de Jong JM, van der Klis RJ, Masurel N, Ligthart GJ. 1999. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol 34:109-115.
Remarque EJ, van Beek WCA, Ligthart GJ, Borst RJA, Nagelkerken L, Palache AM, Sprenger MJW, Masurel N. 1993. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high-dose vaccines. Vaccine 11:649-654.
Wesselius-de Casparis A, Masurel N, Kerrebijn KF. 1972. Field trial with human and equine influenza vaccines in children; protection and antibody titers. Bull World Health Organ 46:151.
Palache AM, Beyer WEPh, Sprenger MJW, Masurel N, De Jonge S, Vardy A, Charpentier B, Noury J, van Beek WCA, Borst RJA, Ligthart GJ, Keren G, Rubinstein E. 1993. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11:3-9.
Gross PA, Quinnan GV, Weksler ME, Gaerlan PF, Denning CR. 1988. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 36:209-212.
Nicholson KG, Baker DJ, Chakraverty P, Farquhar A, Hurd D, Kent J, Litton PA, Smith SH. 1992. Immunogenicity of inactivated influenza vaccine in residential homes for elderly people. Age Ageing 21:182-188.
Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger LB. 1985. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 253:1136-1139.
1994; 331
1990; 13
1991; 133
1986; 153
1989; 7
1988; 36
1994; 272
1970; 10
1998; 158
1972; 46
1988; 128
1993; 167
1990; 161
1987; 25
1989; 103
1987; 137
1993; 11
1999; 34
1972; 70
1999; 179
1992; 21
1996; 312
1980; 244
1998; 55
1992; 40
1985; 253
Powers (BIB21) 1992; 40
Govaert (BIB7) 1994; 272
Reuman (BIB26) 1990; 13
Longini (BIB13) 1988; 128
Sullivan (BIB28) 1990; 161
Glezen (BIB6) 1991; 133
Beyer (BIB3) 1989; 7
Gross (BIB8) 1988; 36
Powers (BIB20) 1993; 167
Remarque (BIB25) 1999; 34
Hobson (BIB10) 1972; 70
Coles (BIB5) 1992; 40
Arden (BIB1) 1986; 153
Remarque (BIB24) 1998; 55
Nichol (BIB14) 1994; 331
Levine (BIB12) 1987; 137
Barker (BIB2) 1980; 244
Nicholson (BIB16) 1992; 21
Wesselius-de Casparis (BIB29) 1972; 46
Remarque (BIB22) 1993; 11
Gross (BIB9) 1987; 25
Peters (BIB19) 1988; 36
de Bruijn (BIB4) 1999; 179
Nichol (BIB15) 1998; 158
Remarque (BIB23) 1996; 312
Katz (BIB11) 1970; 10
Palache (BIB17) 1993; 11
Patriarca (BIB18) 1985; 253
Sprenger (BIB27) 1989; 103
References_xml – reference: Beyer WEPh, Palache AM, Baljet M, Masurel N. 1989. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7:385-394.
– reference: Remarque EJ, de Bruijn IA, Boersma WJA, Masurel N, Ligthart GJ. 1998. Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J Med Virol 55:82-87.
– reference: Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene Cambridge 70:767-777.
– reference: Remarque EJ, de Jong JM, van der Klis RJ, Masurel N, Ligthart GJ. 1999. Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Exp Gerontol 34:109-115.
– reference: Peters NL, Meiklejohn G, Jahnigen DW. 1988. Antibody response of an elderly population to a supplemental dose of influenza B vaccine. J Am Geriatr Soc 36:593-599.
– reference: Sprenger MJW, van Naelten MAMG, Mulder PGH, Masurel N. 1989. Influenza mortality and excess deaths in the elderly, 1967-82. Epidemiol Infect 103:633-641.
– reference: Sullivan KM, Monto AS, Foster DA. 1990. Antibody response to inactivated influenza vaccines of various antigenic concentrations. J Infect Dis 161:333-335.
– reference: Reuman PD, Bernstein DI, Keely SP, Sherwood JR, Young EC, Schiff GM. 1990. Influenza-specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition. Antiviral Res 13:103-110.
– reference: Levine M, Beattie BL, McLean DM. 1987. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ 137:722-726.
– reference: de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJD, Westendorp RGJ, Knook DL. 1999. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 179:31-36.
– reference: Arden NH, Patriarca PA, Lui K-J, Harmon MW, Brandon FB, Kendal AP. 1986. Safety and immunogenicity of a 45 μg supplemental dose of inactivated split-virus Influenza B vaccine in the elderly. J Infect Dis 153:805-806.
– reference: Gross PA, Weksler ME, Quinnan GV, Douglas RG, Gaerlan PF, Denning CR. 1987. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 25:1763-1765.
– reference: Powers DC, Belshe RB. 1993. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 167:584-592.
– reference: Wesselius-de Casparis A, Masurel N, Kerrebijn KF. 1972. Field trial with human and equine influenza vaccines in children; protection and antibody titers. Bull World Health Organ 46:151.
– reference: Remarque EJ, van Beek WCA, Ligthart GJ, Borst RJA, Nagelkerken L, Palache AM, Sprenger MJW, Masurel N. 1993. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high-dose vaccines. Vaccine 11:649-654.
– reference: Coles FB, Balzano GJ, Morse DL. 1992. An outbreak of influenza A (H3N2) in a well immunized nursing home population. J Am Geriatr Soc 40:589-592.
– reference: Longini IM, Koopman JS, Haber M, Cotsonis GA. 1988. Statistical interference for infectious diseases. Risk-specific household and community transmission parameters. Am J Epidemiol 128:845-859.
– reference: Nichol KL, Wuorenma J, von Sternberg T. 1998. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158:1769-1776.
– reference: Nichol KL, Margolis KL, Wuorenma J, von Sternberg TL. 1994. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331:778-784.
– reference: Remarque EJ, Cools HJM, Boere TJ, van der Klis RJ, Masurel N, Ligthart GJ. 1996. Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home. Br Med J 312:1015-1015.
– reference: Barker WH, Mullooly JP. 1980. Influenza vaccination of elderly persons: reduction in pneumonia an influenza hospitalizations and deaths. JAMA 244:2547-2549.
– reference: Katz S, Downs TD, Cash HR, Grotz RC. 1970. Progress in the development of the index of ADL. Gerontologist 10:20-30.
– reference: Gross PA, Quinnan GV, Weksler ME, Gaerlan PF, Denning CR. 1988. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 36:209-212.
– reference: Palache AM, Beyer WEPh, Sprenger MJW, Masurel N, De Jonge S, Vardy A, Charpentier B, Noury J, van Beek WCA, Borst RJA, Ligthart GJ, Keren G, Rubinstein E. 1993. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11:3-9.
– reference: Nicholson KG, Baker DJ, Chakraverty P, Farquhar A, Hurd D, Kent J, Litton PA, Smith SH. 1992. Immunogenicity of inactivated influenza vaccine in residential homes for elderly people. Age Ageing 21:182-188.
– reference: Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger LB. 1985. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 253:1136-1139.
– reference: Powers DC, Murphy BR, Fries LF, Adler WH, Clements ML. 1992. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 40:163-167.
– reference: Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. 1991. Age distribution of patients with medically-attended illness caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 133:296-304.
– reference: Govaert ThME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. 1994. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 272:1661-1665.
– volume: 312
  start-page: 1015
  year: 1996
  end-page: 1015
  article-title: Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home
  publication-title: Br Med J
– volume: 179
  start-page: 31
  year: 1999
  end-page: 36
  article-title: Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination
  publication-title: J Infect Dis
– volume: 7
  start-page: 385
  year: 1989
  end-page: 394
  article-title: Antibody induction by influenza vaccines in the elderly: a review of the literature
  publication-title: Vaccine
– volume: 25
  start-page: 1763
  year: 1987
  end-page: 1765
  article-title: Immunization of elderly people with two doses of influenza vaccine
  publication-title: J Clin Microbiol
– volume: 11
  start-page: 649
  year: 1993
  end-page: 654
  article-title: Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing‐home residents by the use of high‐dose vaccines
  publication-title: Vaccine
– volume: 137
  start-page: 722
  year: 1987
  end-page: 726
  article-title: Comparison of one‐ and two‐dose regimens of influenza vaccine for elderly men
  publication-title: CMAJ
– volume: 21
  start-page: 182
  year: 1992
  end-page: 188
  article-title: Immunogenicity of inactivated influenza vaccine in residential homes for elderly people
  publication-title: Age Ageing
– volume: 133
  start-page: 296
  year: 1991
  end-page: 304
  article-title: Age distribution of patients with medically‐attended illness caused by sequential variants of influenza A/H1N1: comparison to age‐specific infection rates, 1978–1989
  publication-title: Am J Epidemiol
– volume: 13
  start-page: 103
  year: 1990
  end-page: 110
  article-title: Influenza‐specific ELISA IgA and IgG predict severity of influenza disease in subjects prescreened with hemagglutination inhibition
  publication-title: Antiviral Res
– volume: 153
  start-page: 805
  year: 1986
  end-page: 806
  article-title: Safety and immunogenicity of a 45 μg supplemental dose of inactivated split‐virus Influenza B vaccine in the elderly
  publication-title: J Infect Dis
– volume: 11
  start-page: 3
  year: 1993
  end-page: 9
  article-title: Antibody response after influenza immunization with various vaccine doses: a double‐blind, placebo‐controlled, multi‐centre, dose‐response study in elderly nursing‐home residents and young volunteers
  publication-title: Vaccine
– volume: 70
  start-page: 767
  year: 1972
  end-page: 777
  article-title: The role of serum hemagglutination‐inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
  publication-title: Journal of Hygiene Cambridge
– volume: 128
  start-page: 845
  year: 1988
  end-page: 859
  article-title: Statistical interference for infectious diseases. Risk‐specific household and community transmission parameters
  publication-title: Am J Epidemiol
– volume: 244
  start-page: 2547
  year: 1980
  end-page: 2549
  article-title: Influenza vaccination of elderly persons: reduction in pneumonia an influenza hospitalizations and deaths
  publication-title: JAMA
– volume: 10
  start-page: 20
  year: 1970
  end-page: 30
  article-title: Progress in the development of the index of ADL
  publication-title: Gerontologist
– volume: 55
  start-page: 82
  year: 1998
  end-page: 87
  article-title: Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay
  publication-title: J Med Virol
– volume: 36
  start-page: 209
  year: 1988
  end-page: 212
  article-title: Immunization of elderly people with high doses of influenza vaccine
  publication-title: J Am Geriatr Soc
– volume: 46
  start-page: 151
  year: 1972
  article-title: Field trial with human and equine influenza vaccines in children; protection and antibody titers
  publication-title: Bull World Health Organ
– volume: 331
  start-page: 778
  year: 1994
  end-page: 784
  article-title: The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
  publication-title: N Engl J Med
– volume: 158
  start-page: 1769
  year: 1998
  end-page: 1776
  article-title: Benefits of influenza vaccination for low‐, intermediate‐, and high‐risk senior citizens
  publication-title: Arch Intern Med
– volume: 34
  start-page: 109
  year: 1999
  end-page: 115
  article-title: Dose‐dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients
  publication-title: Exp Gerontol
– volume: 161
  start-page: 333
  year: 1990
  end-page: 335
  article-title: Antibody response to inactivated influenza vaccines of various antigenic concentrations
  publication-title: J Infect Dis
– volume: 36
  start-page: 593
  year: 1988
  end-page: 599
  article-title: Antibody response of an elderly population to a supplemental dose of influenza B vaccine
  publication-title: J Am Geriatr Soc
– volume: 40
  start-page: 163
  year: 1992
  end-page: 167
  article-title: Reduced infectivity of cold‐adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies
  publication-title: J Am Geriatr Soc
– volume: 272
  start-page: 1661
  year: 1994
  end-page: 1665
  article-title: The efficacy of influenza vaccination in elderly individuals: a randomized double‐blind placebo‐controlled trial
  publication-title: JAMA
– volume: 103
  start-page: 633
  year: 1989
  end-page: 641
  article-title: Influenza mortality and excess deaths in the elderly, 1967–82
  publication-title: Epidemiol Infect
– volume: 40
  start-page: 589
  year: 1992
  end-page: 592
  article-title: An outbreak of influenza A (H3N2) in a well immunized nursing home population
  publication-title: J Am Geriatr Soc
– volume: 253
  start-page: 1136
  year: 1985
  end-page: 1139
  article-title: Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic
  publication-title: JAMA
– volume: 167
  start-page: 584
  year: 1993
  end-page: 592
  article-title: Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine
  publication-title: J Infect Dis
– volume: 10
  start-page: 20
  year: 1970
  ident: BIB11
  publication-title: Gerontologist
  doi: 10.1093/geront/10.1_Part_1.20
– volume: 137
  start-page: 722
  year: 1987
  ident: BIB12
  publication-title: CMAJ
– volume: 7
  start-page: 385
  year: 1989
  ident: BIB3
  publication-title: Vaccine
  doi: 10.1016/0264-410X(89)90150-3
– volume: 272
  start-page: 1661
  year: 1994
  ident: BIB7
  publication-title: JAMA
  doi: 10.1001/jama.1994.03520210045030
– volume: 13
  start-page: 103
  year: 1990
  ident: BIB26
  publication-title: Antiviral Res
  doi: 10.1016/0166-3542(90)90026-4
– volume: 70
  start-page: 767
  year: 1972
  ident: BIB10
  publication-title: Journal of Hygiene Cambridge
  doi: 10.1017/S0022172400022610
– volume: 21
  start-page: 182
  year: 1992
  ident: BIB16
  publication-title: Age Ageing
  doi: 10.1093/ageing/21.3.182
– volume: 253
  start-page: 1136
  year: 1985
  ident: BIB18
  publication-title: JAMA
  doi: 10.1001/jama.1985.03350320060017
– volume: 25
  start-page: 1763
  year: 1987
  ident: BIB9
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.25.9.1763-1765.1987
– volume: 128
  start-page: 845
  year: 1988
  ident: BIB13
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a115038
– volume: 40
  start-page: 163
  year: 1992
  ident: BIB21
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.1992.tb01938.x
– volume: 133
  start-page: 296
  year: 1991
  ident: BIB6
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a115874
– volume: 11
  start-page: 649
  year: 1993
  ident: BIB22
  publication-title: Vaccine
  doi: 10.1016/0264-410X(93)90311-K
– volume: 161
  start-page: 333
  year: 1990
  ident: BIB28
  publication-title: J Infect Dis
  doi: 10.1093/infdis/161.2.333
– volume: 312
  start-page: 1015
  year: 1996
  ident: BIB23
  publication-title: Br Med J
  doi: 10.1136/bmj.312.7037.1015
– volume: 11
  start-page: 3
  year: 1993
  ident: BIB17
  publication-title: Vaccine
  doi: 10.1016/0264-410X(93)90333-S
– volume: 36
  start-page: 593
  year: 1988
  ident: BIB19
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.1988.tb06152.x
– volume: 36
  start-page: 209
  year: 1988
  ident: BIB8
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.1988.tb01802.x
– volume: 153
  start-page: 805
  year: 1986
  ident: BIB1
  publication-title: J Infect Dis
  doi: 10.1093/infdis/153.4.805
– volume: 46
  start-page: 151
  year: 1972
  ident: BIB29
  publication-title: Bull World Health Organ
– volume: 244
  start-page: 2547
  year: 1980
  ident: BIB2
  publication-title: JAMA
  doi: 10.1001/jama.1980.03310220045026
– volume: 167
  start-page: 584
  year: 1993
  ident: BIB20
  publication-title: J Infect Dis
  doi: 10.1093/infdis/167.3.584
– volume: 103
  start-page: 633
  year: 1989
  ident: BIB27
  publication-title: Epidemiol Infect
  doi: 10.1017/S0950268800031034
– volume: 331
  start-page: 778
  year: 1994
  ident: BIB14
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199409223311206
– volume: 34
  start-page: 109
  year: 1999
  ident: BIB25
  publication-title: Exp Gerontol
  doi: 10.1016/S0531-5565(98)00060-6
– volume: 179
  start-page: 31
  year: 1999
  ident: BIB4
  publication-title: J Infect Dis
  doi: 10.1086/314540
– volume: 158
  start-page: 1769
  year: 1998
  ident: BIB15
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.158.16.1769
– volume: 40
  start-page: 589
  year: 1992
  ident: BIB5
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.1992.tb02108.x
– volume: 55
  start-page: 82
  year: 1998
  ident: BIB24
  publication-title: J Med Virol
  doi: 10.1002/(SICI)1096-9071(199805)55:1<82::AID-JMV13>3.0.CO;2-1
SSID ssj0008922
Score 1.7655791
Snippet Responses to influenza vaccination are poor in frail elderly subjects who suffer the greatest morbidity and mortality due to infection. Therefore, a randomized...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 293
SubjectTerms Aged
Aged, 80 and over
Antibodies, Viral - blood
Biological and medical sciences
Epidemiology. Vaccinations
Female
General aspects
Humans
immunization
Immunization, Secondary
Infectious diseases
influenza
Influenza A virus - immunology
Influenza B virus - immunology
Influenza Vaccines - administration & dosage
Influenza virus
Influenza, Human - blood
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Male
Medical sciences
Netherlands - epidemiology
nursing home
Orthomyxoviridae - immunology
randomized controlled trial
Vaccination
Title Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects
URI https://api.istex.fr/ark:/67375/WNG-2L9L2QMX-6/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2F1096-9071%28200104%2963%3A4%3C293%3A%3AAID-JMV1004%3E3.0.CO%3B2-C
https://www.ncbi.nlm.nih.gov/pubmed/11241460
https://www.proquest.com/docview/17846458
https://www.proquest.com/docview/76952621
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3db9MwELemIU288P0RGOAHiuDBXWwncVIQ0ggbo1o7MQ3om2UnjlStJKhp-ejfwR_MOU5bisYDEkKKlChKfPLPd-dzfPkdQo8tJ1wRRjlJNMtJQDUlCSsMYaxQItBhmDdceoNhdPQ-6I_C0Raql__COH6I1Qc3axmNv7YGrnS9tyYNpRB8E1jagcHHrKGZgbVzxGFggw5PYRaDKzj2374m_cEHS4zW4Qe863fTkw5_xUgKftvmeNlA6nRNORUnbucBPAiBuSvcQUkrc28l8amT9yziveAFSOr1fpHy0sl4DhI25rpLdti-2dxLVQP8haubcVFguxknNxPd4VX0YwmRy285785nupstfmOP_M8YXkNX2sAZ7ztNv462THkD7Qza1ICb6OupKvPq03hhctzm30_gsqlKgqsCg6lVU5cQbGo8q3BezfXEwKk2GF7FsNywpBF47Mq2LBT-ojJou1FduIsBy_EEG1vWfPId13NtP2HVt9DZ4cFZekTaqhIks-yEREcsEX4GqwrOcwhXjY1wYlokNCt8I6jRipooDsH7-TmnRWCLsNNAhCZXNBf8Ntouq9LcRZhzwTSEy4Izbv_Y1UwYFquCZyH4wTjzUH85_PKz4w6RjiWa2Y3_SFrkpcNdRlwGEhCXEtCWLdqSS1-mJ5LJ1ENPGgVataSm5zYpT4Ty4_CNZMfJMXs3GMnIQ7sbGrZ6IWGWC8lDj5YKJ8GT2O0hVZpqXksqYrvNHf_5CRElgAWjHrrjNHXdLQARLMb30LDRt7_o78XdXd66968bvI8uuzRCm3y1i7Zn07l5AHHlTD9sHMFPSIZWEw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3db9MwELfGJg1e-P4IDOYHiuAhXWwncVIQ0sg2utF22lSgb1Y-HKlaaVDT8tH_g_-XuzhtKRoPSAipUqMo8ck_353P9uV3hDxFTrjc8zM7THhmuyxhdshzbXOex9JNPC-ruPS6Pb_93j0ZeIMNMl18C2P4IZYbbmgZlb9GA8cN6b0VayiD6NuGtR1YfMArnhlYPPsCRtZtiAimMbiC3_7xgX3S_YDMaA1xKJpOMzptiDfcjq6QLawEjnUPDs5XpFNBaM4ewIfYMHt52ySshe4tRT43Al_4ouW-AlGt1i9iXhshL0HE2my3hQP3DbMv4xIGIDeVMy4Lbdcj5WqqO7pBfixAMhkuF83ZNGmm89_4I_83ijfJ9Tp2pvtG2W-RDT2-Tba7dXbAHfL1PB5nxafhXGe0TsEfwWVVmIQWOQVrKyYmJ1iXdFrQrJglIw1_pabwKoUVB_JG0KGp3DKP6Zc4hbYr7YW7FMAcjqjGyuaj77ScJbiLVd4l_aPDftS268ISdooEhXbi81A6KSwshMggYtUY5AQsD1maO1oyncRM-4EHDtDJBMtdrMPOXOnpLGaZFPfI5rgY6weECiF5AhGzFFzgR7sJl5oHcS5SD1xhkFrkZDH-6rOhD1GGKJrj2b-vEHllcFe-UK4CxJUCtFWNthLKUdGp4iqyyLNKg5YtxZMLzMuTnvrYe6t4J-zws-5A-RbZWVOx5QshRzoki-wuNE6BM8ETonisi1mpmAzwpDv48xPSDwELzixy36jqqlsAIpiMY5FepXB_0d_Lu7u49fBfN7hLrrb73Y7qHPfePSLXTFYh5mLtkM3pZKYfQ5g5TZ5UXuEnv1RaLQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3db9MwELfGJk288P0RGMwPFMFDuthO4qQgpJGtbKXtYBrQNyuOHalaaaam5aN_B38w5zhtKRoPSAgpUqIo8ck_353P8eV3CD0xnHB5ECo3llS5PpHEjWmuXUrzlPsyCFTFpdfrh0cf_M4gGGygcvEvjOWHWH5wM5ZR-Wtj4Bcq31uRhhIIvl1Y2oHBR7SimYG1c8hgYP0GS2AWgys49o8P3E7voyFGa7BD1vSayUmDvaZucgVt-SEYmYmkTlecU1Fstx7AhbgweQXbKK6F7i1FPrMCn4es5b8EUa3WL2JeWSEvQMTaZLdlxu2bSb5MS8A_t4UzLots1wPlaqZrX0c_FhjZBJfz5mwqm9n8N_rI_wziDXStjpzxvlX1m2hDj2-h7V6dG3AbfT1Nx6r4PJxrhesE_BFcVmVJcJFjsLViYjOCdYmnBVbFTI40nEqN4VUM6w3DGoGHtm7LPMVf0gzarnQX7mLAcjjC2tQ1H33H5Uyab1jlHXTWPjxLjty6rISbGXpCV4Y05l4GywrGFMSr2oQ4EcljkuWe5kTLlOgwCsD9eYqR3DdV2InPA61Soji7izbHxVjfR5gxTiXEy5xRZn7ZlZRrGqU5ywJwhFHmoM5i-MWFJQ8Rliaamp3_UBjkhcVdhEz4AhAXAtAWNdqCCU8kJ4KKxEFPKwVatpROzk1WHg_Ep_4bQbtxl77vDUTooJ01DVu-EFNDhuSg3YXCCXAlZn8oHetiVgrCI7PPHf35CR7GgAUlDrpnNXXVLQARLMZzUL_St7_o7-XdXdx68K8b3EXb7w7aonvcf_sQXbUphSYRawdtTicz_QhizKl8XPmEn1ZvWOU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+controlled+trial+of+seroresponses+to+double+dose+and+booster+influenza+vaccination+in+frail+elderly+subjects&rft.jtitle=Journal+of+medical+virology&rft.au=Roos%E2%80%90van+Eijndhoven%2C+D.G.&rft.au=Cools%2C+H.J.M.&rft.au=Westendorp%2C+R.G.J.&rft.au=Ten+Cate%E2%80%90Hoek%2C+A.J.&rft.date=2001-04-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=63&rft.issue=4&rft.spage=293&rft.epage=298&rft_id=info:doi/10.1002%2F1096-9071%28200104%2963%3A4%3C293%3A%3AAID-JMV1004%3E3.0.CO%3B2-C&rft.externalDBID=10.1002%252F1096-9071%2528200104%252963%253A4%253C293%253A%253AAID-JMV1004%253E3.0.CO%253B2-C&rft.externalDocID=JMV1004
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon